Home > News & Updates

Cancer Biomarker Capture and Elution by Cell Specific Aptamers

15th January 2019

Aptamers have a great potential in cancer biomarker discovery via selection against cancer cells following counter selection against healthy cells. Aptamers were identified to bind to cancer specific biomarkers on cells and then subsequently isolated and analysed.

Prostate cancer cells were lysed and incubated with streptavidin magnetic beads pre-immobilized with a biotinylated single stranded […]

Aptamer Group Announces Agreement with AstraZeneca to Explore Next-Generation Drug Delivery Devices

7th January 2019
Aptamer Group today announced it has signed an agreement with AstraZeneca to explore the potential of using aptamer technology to target the kidney. The two-year agreement will give AstraZeneca use of Aptamer Group’s proprietary technology to explore the feasibility of developing the next generation of drug delivery vehicles, called Aptamer Drug Conjugates (ApDCs).

Aptamers […]

Aptamer Group December 2018

19th December 2018
This month:

Aptamer Group data on selective cell based biomarker aptamers
The year in review, from new product launches to company accolades
Interesting applications in international diagnostics and small molecule lateral flow assays

Novel Solutions – Biomarkers 
Aptamers specific to the same cell type at different stages within a disease cycle

No biomarker abundance restriction
Whole […]

Aptamer Group’s Expansion

14th December 2018

We are proud to announce that we have negotiated an agreement with York Science Park to expand our premises.

The addition of two further laboratories and two offices to our existing space of five labs and four offices will allow us to continue our growth. The additional space has allowed us to set up […]

Aptamer Group November 2018

29th November 2018.
This month:

Aptamer Group data on selective bind and elution reusability of aptamer  purification columns
Small molecule analysis webinar with Pall ForteBio BLI platform
Our CEO Today United Kingdom award
Interesting applications in antibiotic biosensors and ELISA antibody/aptamer pairs

Novel Solutions – Purification 
Reproducibility of aptamers that bind and release under defined conditions

Less expensive
Gentle […]

CEO Today Magazine Awards – Winners

3rd December 2018
Aptamer Group is proud to receive the CEO Today Magazine United Kingdom Awards for distinguished performance by our CEO and Founder Arron Tolley.

The award recognises, identifies and honours the most respected companies and their C-level executives operating within the United Kingdom today. Researchers at CEO Today determine the eligibility of the CEO/Executive based […]

The Microbiology Show 2018

10th October 2018
Our Chief Technical Officer, David Bunka, gave a talk  on how aptamers can be used in microbiology at The Microbiology Show in Derby.

The Microbiology Show brings together the technology, equipment, consultancy and services associated with the field of microbiology together in one event. There were a series of keynote presentations from thought leaders in […]

Clinical Research Organisation

“We first started looking into aptamers last year as we wanted to monitor therapeutic levels In vitro. Working with Aptamer Group showed just how special aptamers really are. Their selection process is very adaptive and the team responded promptly to any questions we had. The aptamers function as required with very good binding affinity and […]

Top 10 Global Pharma

“After trying various alternatives we reached out to Aptamer Group to see if their selection service could help. We were initially impressed by how quickly they responded to our enquiry. We stayed in regular contact throughout the course of the project with regular updates and data to show progress. This communication really helped me feel […]

Diagnostic Company

“ collaborated with the Aptamer Group on an Innovate UK funded project in 2014. We really enjoyed working with the team at Aptamer Group and found them to be very competent scientists as well as nice people to work with. The outcome of the project is still having an influence on our business activities today. […]